Jump To Section
Featured Stories
Moderna, Inovio Coronavirus Vaccine Candidates Fast-Tracked By International Coalition
The Coalition for Epidemic Preparedness Innovations adds new deal with mRNA specialist Moderna for rapid development of coronavirus vaccine.
Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
J.P. Morgan Spotlight
New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development
Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China
A Muted J.P. Morgan, But The Focus Is Execution – And That's Good News
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
On-the-scene coverage from biopharma's biggest annual meeting, plus related articles, updated daily.
Latest News
Recent Tweets from Scrip
Outlook 2020
2020 Vision For Biopharma
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI
The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track
Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.
Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications
Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal
Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China
Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.
JT Gains World-First Topical JAK Inhibitor Approval
Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?
While disappointing result will probably put an end to single-drug development plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
AZ Closer To Second Enhertu OK After Gastric Cancer Success
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.
Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.